Prudential Financial’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Prudential Financial’s Portfolio PSTX Stock Details PSTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-19,980	Closed	-$192K	–	2412
2024 Q4	$192K	Hold	19,980	–	–	﹤0.01%	2099
2024 Q3	$57.1K	Hold	19,980	–	–	﹤0.01%	2634
2024 Q2	$58.3K	Buy	+19,980	New	+$54.6K	﹤0.01%	2596
2024 Q1	–	Sell	-24,380	Closed	-$81.9K	–	2772
2023 Q4	$81.9K	Hold	24,380	–	–	﹤0.01%	2516
2023 Q3	$58K	Buy	+24,380	New	+$51.1K	﹤0.01%	2487
2023 Q1	–	Sell	-12,600	Closed	-$66.8K	–	2685
2022 Q4	$66.8K	Hold	12,600	–	–	﹤0.01%	2475
2022 Q3	$44K	Buy	+12,600	New	+$41.7K	﹤0.01%	2566

Other funds holding PSTX

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Prudential Financial's PSTX Position: Q1 2025 in Review

Prudential Financial sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2025, closing a stake of 19,980 shares — an estimated $192K sold.

Prudential Financial first reported a position in PSTX in Q3 2022 and held it in 7 quarters. The position peaked at $192K in Q4 2024. 1 fund tracked by Wall St. Rank holds PSTX as of Q1 2025.

Prudential Financial reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
Prudential Financial sold 19,980 Poseida Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $192K.
Prudential Financial first reported a position in Poseida Therapeutics, Inc. Common Stock in Q3 2022 and held it in 7 quarters.
Prudential Financial's Poseida Therapeutics, Inc. Common Stock position peaked at $192K in Q4 2024.
1 fund tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2025.

Based on Prudential Financial's 13F filing for Q1 2025, filed 13 May 2025.